Key result
DCB-only and DCB-hybrid CTO PCI showed no significant difference in relative risk for major cardiovascular events compared with DES/bioadaptor-only PCI over 13 months.
Why the study?
Does a drug-coated balloon (DCB) only or DCB-hybrid strategy compare favorably in terms of composite MACE (cardiovascular death, myocardial infarction, stroke, and unplanned target vessel revascularization) to a drug-eluting stent (DES)/bioadaptor only strategy in patients undergoing successful elective CTO PCI?
Cohort (n=131)
No
Does a drug-coated balloon (DCB) only or DCB-hybrid strategy compare favorably in terms of composite MACE (cardiovascular death, myocardial infarction, stroke, and unplanned target vessel revascularization) to a drug-eluting stent (DES)/bioadaptor only strategy in patients undergoing successful elective CTO PCI?
In patients undergoing successful elective CTO PCI, DCB-only and DCB-hybrid strategies showed comparable safety and 13-month MACE rates to a DES/bioadaptor-only strategy.
Answers are grounded in this paper and cite their sources.
No MACE difference observed with DCB versus DES strategies in CTO PCI; leaves open their comparative safety and efficacy pending randomized trials.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Hadžibegović et al. (2026) conducted a cohort in Chronic total occlusion (CTO) undergoing percutaneous coronary intervention (PCI) (n=131). Drug-coated balloon (DCB) only or DCB-hybrid CTO PCI strategy vs. Drug-eluting stent (DES) or bioadaptor only CTO PCI strategy was evaluated on Composite MACE of cardiovascular death, myocardial infarction, stroke, and unplanned target vessel revascularization. DCB-only and DCB-hybrid CTO PCI showed no significant difference in relative risk for major cardiovascular events compared with DES/bioadaptor-only PCI over 13 months.
Synapse has enriched 10 related papers. Consider them for comparative context: